- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05582395
Um estudo de Mavacamten em cardiomiopatia hipertrófica não obstrutiva (ODYSSEY-HCM)
Um estudo clínico randomizado, duplo-cego e controlado por placebo para avaliar Mavacamten em adultos com cardiomiopatia hipertrófica não obstrutiva sintomática
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 13353
- Local Institution - 0403
-
Freiburg im Breisgau, Alemanha, 79106
- Local Institution - 0071
-
Hamburg, Alemanha, 20246
- Local Institution - 0032
-
Heidelberg, Alemanha, 69120
- Local Institution - 0077
-
München, Alemanha, 80636
- Local Institution - 0454
-
Münster, Alemanha, 48149
- Local Institution - 0046
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Alemanha, 89081
- Local Institution - 0404
-
-
Bavaria
-
München, Bavaria, Alemanha, 81377
- Local Institution - 0022
-
Regensburg, Bavaria, Alemanha, 93053
- Local Institution - 0440
-
-
Hesse
-
Bad Nauheim, Hesse, Alemanha, 61231
- Local Institution - 0013
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Alemanha, 37075
- Local Institution - 0496
-
Hanover, Lower Saxony, Alemanha, 30625
- Local Institution - 0448
-
-
North Rhine Wesrphalia
-
Cologne, North Rhine Wesrphalia, Alemanha, 50924
- Local Institution - 0273
-
-
North Rhine-Westphalia
-
Bad Oeynhausen, North Rhine-Westphalia, Alemanha, 32545
- Local Institution - 0439
-
Bielefeld, North Rhine-Westphalia, Alemanha, 33604
- Local Institution - 0174
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Alemanha, 55131
- Local Institution - 0420
-
-
Schleswig-Holstein
-
Lübeck, Schleswig-Holstein, Alemanha, 23538
- Local Institution - 0066
-
-
Thuringia
-
Jena, Thuringia, Alemanha, 07747
- Local Institution - 0016
-
-
-
-
New South Wales
-
Concord, New South Wales, Austrália, 2139
- Local Institution - 0063
-
Darlinghurst, New South Wales, Austrália, 2010
- Local Institution - 0085
-
Sydney, New South Wales, Austrália, 2170
- Local Institution - 0369
-
-
Queensland
-
Chermside, Queensland, Austrália, 4032
- Local Institution - 0080
-
Milton, Queensland, Austrália, 4064
- Local Institution - 0078
-
-
South Australia
-
Bedford Park, South Australia, Austrália, 5042
- Local Institution - 0050
-
-
Western Australia
-
Murdoch, Western Australia, Austrália, 6150
- Local Institution - 0076
-
-
-
-
-
Rio de Janeiro, Brasil, 22061-080
- Local Institution - 0451
-
Rio de Janeiro, Brasil, 20551-030
- Local Institution - 0446
-
São Paulo, Brasil, 04012-180
- Local Institution - 0418
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 40170-130
- Local Institution - 0413
-
-
Federal District
-
Brasília, Federal District, Brasil, 70710-140
- Local Institution - 0438
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30220-140
- Local Institution - 0488
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90560-030
- Local Institution - 0447
-
Porto Alegre, Rio Grande do Sul, Brasil, 90620-001
- Local Institution - 0450
-
-
São Paulo
-
Bragança Paulista, São Paulo, Brasil, 12916-542
- Local Institution - 0430
-
Ribeirão Preto, São Paulo, Brasil, 14026-900
- Local Institution - 0422
-
São Paulo, São Paulo, Brasil, 05403-000
- Local Institution - 0412
-
-
-
-
Antwerpen
-
Edegem, Antwerpen, Bélgica, 2650
- Local Institution - 0462
-
-
Brussels Capital
-
Anderlecht, Brussels Capital, Bélgica, 1070
- Local Institution - 0034
-
-
Limburg
-
Genk, Limburg, Bélgica, 3600
- Local Institution - 0476
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Bélgica, 3000
- Local Institution - 0319
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 1N4
- Local Institution - 0381
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6E 1M7
- Local Institution - 0467
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8L 2X2
- Local Institution - 0414
-
London, Ontario, Canadá, N6A 5A5
- Local Institution - 0411
-
-
Quebec
-
Québec, Quebec, Canadá, G1V 4G5
- Local Institution - 0093
-
-
-
-
-
Beijing, China, 100730
- Local Institution - 0502
-
Beijing, China, 102218
- Local Institution - 0553
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100083
- Local Institution - 0535
-
Beijing, Beijing Municipality, China, 100730
- Local Institution - 0534
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400016
- Local Institution - 0503
-
Chongqing, Chongqing Municipality, China, 400016
- Local Institution - 0541
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Local Institution - 0539
-
Guangzhou, Guangdong, China, 510515
- Local Institution - 0543
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Local Institution - 0549
-
-
Hubei
-
Wuhan, Hubei, China, 430060
- Local Institution - 0542
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Local Institution - 0548
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Local Institution - 0545
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330008
- Local Institution - 0550
-
-
Jilin
-
Changchun, Jilin, China, 130041
- Local Institution - 0544
-
-
Liaoning
-
Dalian, Liaoning, China, 116011
- Local Institution - 0540
-
Shenyang, Liaoning, China, 110016
- Local Institution - 0501
-
Shenyang, Liaoning, China, 110016
- Local Institution - 0538
-
-
Shan1xi
-
Xi'an, Shan1xi, China, 710061
- Local Institution - 0547
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Local Institution - 0546
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200127
- Local Institution - 0537
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Local Institution - 0533
-
Chengdu, Sichuan, China, 610015
- Local Institution - 0552
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- Local Institution - 0536
-
-
-
-
-
Busan, Coréia do Sul, 49241
- Local Institution - 0517
-
Seongnam-si, Coréia do Sul
- Local Institution - 0508
-
Seoul, Coréia do Sul, 03080
- Local Institution - 0217
-
Seoul, Coréia do Sul, 05505
- Local Institution - 0049
-
-
Daegu Gwang'yeogsi
-
Daegu, Daegu Gwang'yeogsi, Coréia do Sul, 42601
- Local Institution - 0516
-
-
Incheon Gwang'yeogsi
-
Incheon, Incheon Gwang'yeogsi, Coréia do Sul, 22332
- Local Institution - 0518
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Coréia do Sul, 03722
- Local Institution - 0012
-
Seoul, Seoul Teugbyeolsi, Coréia do Sul, 6351
- Local Institution - 0055
-
Seoul, Seoul Teugbyeolsi, Coréia do Sul, 6591
- Local Institution - 0460
-
-
-
-
-
Aarhus N, Dinamarca, 8200
- Local Institution - 0019
-
-
North Denmark
-
Aalborg, North Denmark, Dinamarca, DK-9000
- Local Institution - 0045
-
-
Sønderjylland
-
Aabenraa, Sønderjylland, Dinamarca, 6200
- Local Institution - 0428
-
-
-
-
-
A Coruña, Espanha, 15006
- Local Institution - 0043
-
Alicante, Espanha, 03010
- Local Institution - 0087
-
Barcelona, Espanha, 08035
- Local Institution - 0018
-
Barcelona, Espanha, 08036
- Local Institution - 0056
-
Granada, Espanha, 18014
- Local Institution - 0060
-
Madrid, Espanha, 28034
- Local Institution - 0421
-
Málaga, Espanha, 29010
- Local Institution - 0041
-
Salamanca, Espanha, 37007
- Local Institution - 0031
-
Seville, Espanha, 41009
- Local Institution - 0051
-
Valencia, Espanha, 46026
- Local Institution - 0027
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Espanha, 07198
- Local Institution - 0040
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Espanha, 08907
- Local Institution - 0299
-
-
Madrid
-
Majadahonda, Madrid, Espanha, 28222
- Local Institution - 0021
-
-
Murcia
-
El Palmar, Murcia, Espanha, 30120
- Local Institution - 0237
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233-1900
- Local Institution - 0082
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Local Institution - 0458
-
-
California
-
La Jolla, California, Estados Unidos, 92037-1337
- Local Institution - 0409
-
Los Angeles, California, Estados Unidos, 90048-3311
- Local Institution - 0010
-
San Francisco, California, Estados Unidos, 94143-2204
- Local Institution - 0406
-
Stanford, California, Estados Unidos, 94305-2200
- Local Institution - 0079
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32608-1134
- Local Institution - 0468
-
Tampa, Florida, Estados Unidos, 33606-3603
- Local Institution - 0281
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Local Institution - 0092
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202-1243
- Local Institution - 0424
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242-1009
- Local Institution - 0070
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160-8500
- Local Institution - 0410
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40217-1363
- Local Institution - 0484
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Local Institution - 0127
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Local Institution - 0479
-
Boston, Massachusetts, Estados Unidos, 02118-2908
- Local Institution - 0500
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Local Institution - 0464
-
Detroit, Michigan, Estados Unidos, 48202-2608
- Local Institution - 0064
-
Grand Rapids, Michigan, Estados Unidos, 49525
- Local Institution - 0455
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Local Institution - 0431
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Local Institution - 0461
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198-2265
- Local Institution - 0435
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07962
- Local Institution - 0490
-
-
New York
-
Manhasset, New York, Estados Unidos, 11030-3816
- Local Institution - 0449
-
New York, New York, Estados Unidos, 10019-1147
- Local Institution - 0486
-
Stony Brook, New York, Estados Unidos, 11790-3407
- Local Institution - 0007
-
Valhalla, New York, Estados Unidos, 10595
- Local Institution - 0426
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204-2826
- Local Institution - 0094
-
Durham, North Carolina, Estados Unidos, 27710
- Local Institution - 0065
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Local Institution - 0083
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Local Institution - 0047
-
Lancaster, Pennsylvania, Estados Unidos, 17602-2250
- Local Institution - 0444
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Local Institution - 0263
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213-2536
- Local Institution - 0081
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138-1727
- Local Institution - 0207
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- Local Institution - 0089
-
Dallas, Texas, Estados Unidos, 75390
- Local Institution - 0365
-
Plano, Texas, Estados Unidos, 75093
- Local Institution - 0492
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84132-0001
- Local Institution - 0402
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908-0001
- Local Institution - 0478
-
Richmond, Virginia, Estados Unidos, 23298-5024
- Local Institution - 0095
-
-
-
-
-
Nantes, França, 44093
- Local Institution - 0009
-
Paris, França, 75013
- Local Institution - 0004
-
Paris, França, 75015
- Local Institution - 0006
-
Pessac, França, 33604
- Local Institution - 0053
-
Rennes, França, 35000
- Local Institution - 0008
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, França, 06000
- Local Institution - 0001
-
-
Finistère
-
Brest, Finistère, França, 29200
- Local Institution - 0463
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, França, 31400
- Local Institution - 0005
-
-
Indre-et-Loire
-
Chambray-lès-Tours, Indre-et-Loire, França, 37044
- Local Institution - 0003
-
-
Isère
-
La Tronche, Isère, França, 38700
- Local Institution - 0489
-
-
Rhône
-
Bron, Rhône, França, 69500
- Local Institution - 0067
-
-
-
-
-
Utrecht, Holanda, 3584 CX
- Local Institution - 0061
-
-
Gelderland
-
Nijmegen, Gelderland, Holanda, 6525 GA
- Local Institution - 0442
-
-
Limburg
-
Maastricht, Limburg, Holanda, 6229 HX
- Local Institution - 0434
-
-
North Holland
-
Amsterdam-Zuidoost, North Holland, Holanda, 1105 AZ
- Local Institution - 0197
-
-
South Holland
-
Rotterdam, South Holland, Holanda, 3015 GD
- Local Institution - 0213
-
-
-
-
-
Budapest, Hungria, 1096
- Local Institution - 0048
-
Budapest, Hungria, 1097
- Local Institution - 0039
-
Budapest, Hungria, 1122
- Local Institution - 0035
-
Szeged, Hungria, 6720
- Local Institution - 0417
-
-
Veszprém megye
-
Balatonfüred, Veszprém megye, Hungria, 8230
- Local Institution - 0423
-
-
-
-
-
Haifa, Israel, 3109601
- Local Institution - 0419
-
Petah Tikva, Israel, 49100
- Local Institution - 0427
-
Ramat Gan, Israel, 5265601
- Local Institution - 0074
-
Rehovot, Israel, 76100
- Local Institution - 0054
-
Safed, Israel, 13100
- Local Institution - 0253
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 90000
- Local Institution - 0025
-
Jerusalem, Jerusalem, Israel, 9103102
- Local Institution - 0057
-
-
Tel Aviv
-
Ashkelon, Tel Aviv, Israel, 7830604
- Local Institution - 0026
-
Tel Aviv, Tel Aviv, Israel, 6423906
- Local Institution - 0037
-
-
-
-
-
Pisa, Itália, 56124
- Local Institution - 0171
-
Roma, Itália, 00189
- Local Institution - 0028
-
-
Tuscany
-
Florence, Tuscany, Itália, 50139
- Local Institution - 0373
-
-
-
-
-
Fukuoka, Japão, 810-0001
- Local Institution - 0521
-
-
Ehime
-
Uwajima, Ehime, Japão, 798-8510
- Local Institution - 0370
-
-
Hyōgo
-
Himeji-Shi, Hyōgo, Japão, 672-8044
- Local Institution - 0208
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japão, 920-8641
- Local Institution - 0457
-
-
Kanagawa
-
Yokohama, Kanagawa, Japão, 227-8501
- Local Institution - 0107
-
-
Kochi
-
Nankoku-shi, Kochi, Japão, 783-8505
- Local Institution - 0119
-
-
Mie-ken
-
Tsu, Mie-ken, Japão, 514-8507
- Local Institution - 0453
-
-
Miyagi
-
Sendai, Miyagi, Japão, 980-8574
- Local Institution - 0456
-
-
Osaka
-
Osaka, Osaka, Japão, 545-0051
- Local Institution - 0452
-
Suita, Osaka, Japão, 564-8565
- Local Institution - 0315
-
Takatsuki-Shi, Osaka, Japão, 569-8686
- Local Institution - 0471
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japão, 431-3192
- Local Institution - 0168
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japão, 1138603
- Local Institution - 0477
-
Chuo-Ku, Tokyo, Japão, 104-0044
- Local Institution - 0505
-
Koto-Ku, Tokyo, Japão, 135-0061
- Local Institution - 0466
-
Shinjuku-ku, Tokyo, Japão, 160-8582
- Local Institution - 0314
-
Shinjuku-ku, Tokyo, Japão, 162-8666
- Local Institution - 0475
-
tabashi City, Tokyo, Japão, 173-0003
- Local Institution - 0224
-
-
-
-
-
Lørenskog, Noruega, 1478
- Local Institution - 0443
-
Oslo, Noruega, 0424
- Local Institution - 0441
-
Trondheim, Noruega, 7030
- Local Institution - 0473
-
-
-
-
-
Bialystok, Polônia, 15-276
- Local Institution - 0030
-
Lódz, Polônia, 93-338
- Local Institution - 0416
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polônia, 31-202
- Local Institution - 0042
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polônia, 50-556
- Local Institution - 0038
-
Wroclaw, Lower Silesian Voivodeship, Polônia, 50-981
- Local Institution - 0091
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polônia, 02-097
- Local Institution - 0338
-
Warsaw, Masovian Voivodeship, Polônia, 02-507
- Local Institution - 0203
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Polônia, 35-055
- Local Institution - 0072
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polônia, 40-555
- Local Institution - 0017
-
Zabrze, Silesian Voivodeship, Polônia, 41-800
- Local Institution - 0415
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polônia, 91-347
- Local Institution - 0059
-
-
-
-
-
Almada, Portugal, 2805-267
- Local Institution - 0015
-
Leiria, Portugal, 2410-197
- Local Institution - 0433
-
Lisbon, Portugal, 1500-650
- Local Institution - 0023
-
Lisbon, Portugal, 1649-035
- Local Institution - 0024
-
Vila Nova de Gaia, Portugal, 4434-502
- Local Institution - 0014
-
-
Braga District
-
Guimarães, Braga District, Portugal, 4835-044
- Local Institution - 0044
-
-
-
-
-
Birmingham, Reino Unido, B15 2TH
- Local Institution - 0407
-
London, Reino Unido, EC1A 7BE
- Local Institution - 0472
-
-
Greater London
-
London, Greater London, Reino Unido, SW3 6NP
- Local Institution - 0445
-
-
Lanarkshire
-
Glasgow, Lanarkshire, Reino Unido, G51 4TF
- Local Institution - 0073
-
-
-
-
-
Brno, Tcheca, 656 91
- Local Institution - 0188
-
-
Hradec Králové Region
-
Broumov, Hradec Králové Region, Tcheca, 550 01
- Local Institution - 0086
-
-
Praha, Hlavní Mesto
-
Prague, Praha, Hlavní Mesto, Tcheca, 140 21
- Local Institution - 0033
-
Prague, Praha, Hlavní Mesto, Tcheca, 128 21
- Local Institution - 0052
-
-
-
-
-
Graz, Áustria, 8036
- Local Institution - 0062
-
Vienna, Áustria, 1090
- Local Institution - 0429
-
-
Tyrol
-
Innsbruck, Tyrol, Áustria, 6020
- Local Institution - 0090
-
-
Upper Austria
-
Linz, Upper Austria, Áustria, 4020
- Local Institution - 0075
-
-
Upper Austria (Oberösterreich)
-
Braunau am Inn, Upper Austria (Oberösterreich), Áustria, 5280
- Local Institution - 0069
-
-
-
-
-
Chandigarh, Índia, 160012
- Local Institution - 0483
-
Gūrgaon, Índia, 122 001
- Local Institution - 0330
-
-
Gujarat
-
Ahmedabad, Gujarat, Índia, 380060
- Local Institution - 0482
-
-
Karnataka
-
Bengaluru, Karnataka, Índia, 560099
- Local Institution - 0480
-
-
Kerala
-
Kochi, Kerala, Índia, 682001
- Local Institution - 0481
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria
- Diagnosis of HCM consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines: unexplained left-ventricular hypertrophy with non-dilated ventricular chambers in the absence of other cardiac or systemic disease which can produce the required magnitude of hypertrophy of a maximal left ventricular (LV) wall thickness ≥ 15 millimeters (mm) (or ≥ 13 mm with positive family history of hypertrophic cardiomyopathy [HCM]) as determined by core laboratory interpretation.
- Peak left ventricular outflow tract (LVOT) pressure gradient < 30 millimeters mercury (mm Hg) at rest and < 50 mm Hg with provocation (Valsalva maneuver and stress echocardiography).
- New York Heart Association (NYHA) Class II or III.
Exclusion Criteria
- Known infiltrative or storage disorder causing cardiac hypertrophy that mimics non-obstructive hypertrophic cardiomyopathy (nHCM) such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy.
- History of unexplained syncope within 6 months prior to screening.
- History of sustained ventricular tachyarrhythmia (> 30 seconds) within 6 months prior to screening.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
|
Specified dose on specified days |
|
Experimental: Mavacamten
|
Specified dose on specified days
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in KCCQ-23 CSS at Week 48
Prazo: From First dose to week 48
|
The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment. |
From First dose to week 48
|
|
Change From Baseline in pVO2 at Week 48
Prazo: From First dose to week 48
|
Clinically meaningful mean change from baseline(1.4ml/kg/min) of pVO2 at Week 48. |
From First dose to week 48
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in VE/VCO2 Slope at Week 48
Prazo: From First dose to week 48
|
VE/VCO₂ slope was assessed using cardiopulmonary exercise testing (CPET). The slope was calculated as the linear regression of minute ventilation (VE) against carbon dioxide production (VCO₂). A decrease in VE/VCO₂ slope reflects improved ventilatory efficiency. |
From First dose to week 48
|
|
Mean Change From Baseline in NT-proBNP to Week 48
Prazo: From First dose to week 48
|
Blood samples were collected for assessing the concentration of NT-proBNP. Baseline is defined as last non-missing measurement prior to the first dose. |
From First dose to week 48
|
|
Percentage of Participants With at Least 1 Class of NYHA Improvement From Baseline at Week 48
Prazo: From First dose to week 48
|
Participants with \>= 1 NYHA function class improvement. The NYHA Functional Classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases. |
From First dose to week 48
|
|
Mean Change From Baseline in HCMSQ SoB Domain Score at Week 48
Prazo: From First dose to week 48
|
The HCMSQ is a self- administered, 9-item questionnaire that assesses the core symptoms of HCM (shortness of breath, tiredness/fatigue, heart palpitations, chest pain, dizziness, and syncope). At each visit, a 7-day period will be defined, ending on the last day with a non-missing HCMSQ score prior to the actual clinic visit (or first dose date if baseline). If the participant completes the HCMSQ for 4 or more days within this period, the weekly average HCMSQ score will be calculated. If fewer than 4 days are completed, other 7-day periods will be considered. For baseline, any 7-day period with at least 4 days of HCMSQ prior to the first dose or randomization date (if first dose date is missing) will be used. Each domain of the SoB scale is scored 1 to 6. The scores are added together to give a total score. Lower scores indicating low to no shortness of breath, higher scores indicating frequent episodes of shortness of breath. the lower the score the better. |
From First dose to week 48
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Bristol-Myers Squibb, Bristol-Myers Squibb
Publicações e links úteis
Publicações Gerais
- Desai MY, Owens AT, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Elliott P, Fernandes F, Verheyen N, Maier L, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Jaber W, Mitchell L, Myers J, Rano T, Gong Z, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Nissen SE; ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11;393(10):961-972. doi: 10.1056/NEJMoa2505927. Epub 2025 Aug 30.
- Desai MY, Nissen SE, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Verheyen N, Wever-Pinzon O, Wolski K, Jaber W, Mitchell L, Davey D, Myers J, Rano T, Bhatia V, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Owens AT; ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM. JACC Heart Fail. 2025 Feb;13(2):358-370. doi: 10.1016/j.jchf.2024.11.013.
- O'Malley PA. Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy. Clin Nurse Spec. 2024 May-Jun 01;38(3):119-121. doi: 10.1097/NUR.0000000000000821. No abstract available.
- Desai MY, Olivotto I, Abraham T, Nissen SE, Garcia-Pavia P, Lopes RD, Elliott PM, Fernandes F, de Barros Correia E, Barriales-Villa R, Zorio E, Arad M, Shin SH, Verheyen N, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Suryawanshi B, Wang Z, Florea V, Aronson R, Owens AT; ODYSSEY-HCM Investigators. Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial. J Am Coll Cardiol. 2025 Dec 16;86(24):2418-2433. doi: 10.1016/j.jacc.2025.08.017. Epub 2025 Aug 27.
- Sikand N, Stendahl J, Sen S, Lampert R, Day S. Current management of hypertrophic cardiomyopathy. BMJ. 2025 May 27;389:e077274. doi: 10.1136/bmj-2023-077274.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CV027-031
- U1111-1269-8581 (Identificador de registro: WHO)
- 2023-506352-24 (Identificador de registro: EU CT Number)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Prazo de Compartilhamento de IPD
See Plan Description
Critérios de acesso de compartilhamento IPD
See Plan Description
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .